Literature DB >> 8245483

Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus.

H Nagafuchi1, N Suzuki, Y Mizushima, T Sakane.   

Abstract

Excessive B cell function including autoantibody production is a common feature of SLE and considered to be intimately associated with spontaneous lymphokine secretion by themselves. To clarify roles of IL-6/IL-6 receptor autocrine activation pathway in autoantibody production observed in patients with SLE, we studied expression and function of IL-6 receptors in comparison with those of IL-2 receptors, Tac on SLE B cells. IL-6 receptors and IL-2 receptors have been detected on B cells in the blood without any in vitro stimuli in most patients with SLE. The introduction of anti-IL-6 receptor antibody, which inhibits binding to the receptors of IL-6, and anti-IL-2 receptor antibody, anti-Tac to the cultures of SLE B cells resulted in potent inhibition of spontaneous production of polyclonal Ig and anti-DNA autoantibodies. In addition, fresh SLE B cells secreted high levels of IL-6 without any in vitro stimuli. These results indicate that constitutive expression of IL-6 receptors on B cells in conjunction with spontaneous IL-6 production by B cells induces autocrine B cell activation, which may lead to B cell hyperactivity and autoantibody secretion in SLE patients. Dysregulation of B cell activity observed in patients with SLE could thus be, at least in part, independent of T cell help.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8245483

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

Review 1.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

2.  IVIg attenuates TLR-9 activation in B cells from SLE patients.

Authors:  Aharon Kessel; Regina Peri; Tharwat Haj; Ayelet Snir; Gleb Slobodin; Edmond Sabo; Itzhak Rosner; Yehuda Shoenfeld; Elias Toubi
Journal:  J Clin Immunol       Date:  2010-10-05       Impact factor: 8.317

Review 3.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

4.  Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors.

Authors:  Raphael Clynes; Nicola Calvani; Byron P Croker; Hanno B Richards
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 5.  IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.

Authors:  B E Barton
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

6.  IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production.

Authors:  Kenichiro Maeda; Harshini Mehta; Douglas A Drevets; K Mark Coggeshall
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

7.  Expression of IL-2R, IL-4R, IL-6R on peripheral blood lymphocytes in systemic lupus erythematosus and correlation with disease activity: a prospective study.

Authors:  E Y Chan; C S Lau; H Zola
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

Review 8.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

Review 9.  B-cell-targeted therapies in systemic lupus erythematosus.

Authors:  Vera Sau-Fong Chan; Helen Hoi-Lun Tsang; Rachel Chun-Yee Tam; Liwei Lu; Chak-Sing Lau
Journal:  Cell Mol Immunol       Date:  2013-01-28       Impact factor: 11.530

Review 10.  Dysregulation of T Follicular Helper Cells in Lupus.

Authors:  John D Mountz; Hui-Chen Hsu; Andre Ballesteros-Tato
Journal:  J Immunol       Date:  2019-03-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.